World News: 13:32 GMT Tuesday 3rd December 2019. [AZTherapies, Inc. via Globe Newswire via SPi World News]
BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- , a biopharmaceutical company developing therapeutics to extend brain health, today announced the publication of preclinical data in demonstrating the anti-inflammatory properties of cromolyn in a mouse model of amyotrophic lateral sclerosis (ALS). The study was conducted by investigators at Massachusetts General Hospital in collaboration with AZTherapies.
The publication, titled “,” supports the potential of targeting neuroinflammation with cromolyn to treat ALS, as evidenced by injected cromolyn’s ability to delay the onset of neurological symptoms, reduce neuroinflammation, decrease the expression of pro-inflammatory cytokines and chemokines, increase spinal cord motor neuron survival, and decrease denervation of muscle in a mouse model of ALS.
“These results further support the hypothesis that inflammation plays a significant role in the progression of ALS,” said lead author Ghazaleh Sadri-Vakili, Ph.D., Director of the NeuroEpigenetics Laboratory at the Sean M. Healey & AMG Center for ALS and the MassGeneral Institute for Neurodegenerative Disease. “We therefore believe that exploring anti-inflammatory treatments may be of great value in developing an effective treatment for the disease.”
“AZTherapies is advancing several clinical candidates that use our re-engineered version of inhaled cromolyn to target the neuroinflammation we believe to be a root cause of a number of serious neurodegenerative diseases, including Alzheimer’s disease and ALS,” said David R. Elmaleh, Ph.D., Founder, CEO, and Chairman of AZTherapies and an author of the publication. “While the exact cause of ALS is not fully understood, accumulating evidence suggests that during both ALS and Alzheimer’s disease progression, cromolyn can shift activated microglia from the aggressive, pro-inflammatory state to a neuroprotective state. These new published data strengthen earlier results and further support the scientific rationale behind our clinical pipeline.”
Dr. Elmaleh continued: “Importantly, unlike commercially available versions of cromolyn, our development programs use a proprietary formulation designed to cross the blood brain barrier and reach critical areas of inflammation. We are currently nearing completion of the Phase 3 clinical trial of our lead program, ALZT-OP1, for the treatment of early Alzheimer’s disease, and we anticipate initiation of a Phase 2a study of our AZT-101 candidate in the treatment of ALS during the first half of 2020.”
Globe Newswire: 13:32 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.